

Special Issue

Marine Origin Agents for Therapy of Neglected Diseases

Message from the Guest Editor

Neglected Tropical Diseases (NTDs) are a group of 17 chronic and disabling infections affecting more than one billion people worldwide, primarily in extreme poor locations. The neglected designation comes from the reduced financial investment into research and development of new drugs, and lack of public awareness in high-income countries. Notwithstanding the recent partial successes in the struggle to eliminate or even eradicate some NTDs, which have been achieved by WHO strategies of disease monitoring, vector control and preventive chemotherapy, the development of new, safe and affordable drugs remains an urgent need. Researchers have turned their attention to nature during the last decades. Marine organisms, including plants thriving in marine environments (halophytes) have been increasingly been recognised over the past few decades as a source of unique and novel biologically active natural products. This Special Issue aims to unlock the potential of marine organisms as sources of novel molecules to control neglected diseases. We welcome submissions from scientists and academics from across the world.

Guest Editor

Dr. Luísa Custódio

Centre of Marine Sciences—CCMAR, University of Algarve, 8005-139 Faro, Portugal

Deadline for manuscript submissions

closed (31 August 2018)



Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



mdpi.com/si/11007

Marine Drugs
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
marinedrugs@mdpi.com

[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)





Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)



About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))